To assess effect measure modification, we stratified on sex, baseline A1C, age at diabetes diagnosis, and diabetes duration.
To examine the presence of effect modification, we stratified the model on age groups, gender, CCI, and history of autoimmune disease.
To test for effect modification, we stratified the analyses on gender, route of infection, race, and CD4 cell count at study inclusion.
In order to further study the relationship between LINE-1 methylation and histone modifications, we stratified histone modifications according to LINE-1 methylation levels.
Third, to assess effect modification, we further stratified the analysis, only among fifth-year students, by medical training-related factors, including basic knowledge about each healthy habit, perception of the school's promotion of each healthy habit, and perceived adequacy of training on each healthy habit.
We did not find any evidence of effect modification when we stratified by younger than 75 years of age compared with older than 75 years of age to explore the associations of the genetic variants with glucose and diabetes.
To explore potential effect measure modification, we performed analyses stratified by age (dichotomised according to median age of controls, i.e., <60 vs ⩾60 years) and gender.
To assess possible effect modification, we explored analyses stratified by age (two categories: < 50 years vs. ≥ 50 years), and BMI (two categories: <25 kg/m vs. ≥25 kg/m).
To consider the possibility of effect modification by sex, we stratified by sex; we restricted the sensitivity analysis to the female subset.
To assess for potential effect modification by AL, we stratified the final multivariate model of blood lead and elevated blood pressure by AL status divided at the median AL score.
To examine potentially differing effects of AKI on mortality in subgroups of ICU patients (effect measure modification) [ 25], we stratified the analyses by age groups, CCI levels, surgical status, CKD, primary hospital diagnosis, and treatment with mechanical ventilation or inotropes/vasopressors.
